In 78 patients with active primary Sjögren's syndrome, iguratimod vs hydroxychloroquine for 24 weeks did not significantly improve SSRI-30 response (57.9% vs 40.0%, p=0.114). Some secondary endpoints favoured iguratimod; adverse events were more frequent (60.6% vs 37.8%).
RCTn = 78
Chen et al. Efficacy and safety of iguratimod in patients with primary Sjögren's syndrome: a multicentre randomised controlled trial